Bryan P. Schneider is an associate professor of medicine at the Indiana University Melvin and Bren Simon Cancer Center. He holds appointments in the Divisions of Hematology/Oncology and Clinical Pharmacology in the Department of Medicine with a secondary appointment in the Department of Medical and Molecular Genetics.
Dr. Schneider completed his medical school, internal medicine residency and hematology/oncology fellowship at Indiana University. Dr. Schneider devotes his clinical time caring for breast cancer patients as a medical oncologist and has a special interest in novel therapeutic agents. He is the model example of a translational scientist as his lab work is both an extension of and complimentary to his clinical interest. His laboratory focus is on pharmacogenetics of breast cancer therapeutics. His biomarker work to date has opened the door for the potential enrichment of patient selection for bevacizumab. Based on his early work, he has designed correlative trials in collaborations with multiple groups to better guide proper patient selection for these agents. He is extensively published in the area of therapeutic individualization (i.e., finding the right drug for each patient). He is a recipient of the prestigious Komen Promise Award and a member of the Komen Scientific Advisory Council. Dr. Schneider is the chair of the Educational Symposium for the Developmental Therapeutics Committee, the vice-chair of the Pharmacogenetics Committee, and a member of the Breast Cancer Committee for the Eastern Cooperative Oncology Group (ECOG). He is also a member of the Consortium on Breast Cancer Pharmacogenetics (CoBRA) and the Pharmacogenetics Research Network (PGRN).